The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

A “life changing” treatment that uses implanted electrodes to stimulate muscles and relieve chronic low back pain is now ...

A common genetic pathway may account for increased risk for atherosclerotic disease in patients with chronic widespread musculoskeletal pain.

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

Having lived with disabling chronic pain for 32 years, one reader discovered a lesser known treatment that has transformed ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

Predicting who will transition from acute to chronic pain is the “holy grail” of pain neuroscience. A novel biomarker ...

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...